GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients

NCT01592279 on ClinicalTrials.gov · last registry update 2012-05-07

124 participants. Its estimated completion date, June 2014, has passed with no update to the record. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hadassah Medical Organization
Sponsor type: Other
Enrollment: 124
Started: 2012-06
Primary completion: 2014-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline.

Conditions studied

Uncontrolled Type 1 Diabetic Patients

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.